Heather Gladue, DO
Rheumatology · Charlotte, NCNPI 1790949642
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $135,006 of the $168,225 with a category attached, or 80.3%. 33 manufacturers reported payments, led by AstraZeneca at 34.0% of the total. Among rheumatology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 807 payments — averaging $208.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$57K
- GSK$55K
- AbbVie$24K
- Boehringer Ingelheim$19K
- Amgen$2K
- Sobi, Inc$2K
- plus $9K from 27 others
What the payments were for
- Consulting fees$10,3006%
- Speaking & faculty fees$135,00680%
- Travel & lodging$7,5805%
- Food & beverage$15,3129%
- Education$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 93 | $57,240 |
| GSK | 58 | $54,712 |
| AbbVie | 86 | $24,022 |
| Boehringer Ingelheim | 8 | $18,679 |
| Amgen(2 entities) | 153 | $2,404 |
| Sobi, Inc | 2 | $2,204 |
| Fresenius Kabi USA, LLC | 4 | $1,361 |
| Novartis | 51 | $1,053 |
| E.r. Squibb & Sons, L.L.C. | 59 | $960 |
| UCB, Inc. | 42 | $860 |
| Lilly USA, LLC | 60 | $809 |
| Johnson & Johnson | 45 | $781 |
| Pfizer | 42 | $724 |
| Actelion Pharmaceuticals US, Inc. | 1 | $525 |
| Radius Health, Inc. | 20 | $372 |
| Genentech USA, Inc. | 17 | $326 |
| Aurinia Pharma U.S., Inc. | 12 | $262 |
| Sanofi | 9 | $167 |
| Mallinckrodt Hospital Products Inc. | 6 | $130 |
| Sandoz | 7 | $118 |
| ANI Pharmaceuticals, Inc. | 5 | $84 |
| Mallinckrodt Enterprises LLC | 3 | $79 |
| Regeneron Healthcare Solutions, Inc. | 5 | $75 |
| Scilex Pharmaceuticals Inc. | 2 | $45 |
| Medexus Pharma, Inc. | 4 | $45 |
| Merck | 3 | $38 |
| Tonix Medicines, Inc. | 2 | $34 |
| Organon | 2 | $33 |
| Pacira Therapeutics, Inc. | 2 | $23 |
| Antares Pharma, Inc. | 1 | $17 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$168,225 in reported general payments places this provider in the 90th percentile of 210 rheumatology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 55 | $603,931 |
| RinvoqUpadacitinib | 59 | $474,028 |
| Enbrel SureclickEtanercept | 60 | $451,086 |
| Humira(Cf) PenAdalimumab | 24 | $258,321 |
| Cimzia (2 Pack)Certolizumab Pegol | 19 | $181,638 |
| Humira PenAdalimumab | 12 | $163,480 |
| OrenciaAbatacept | 22 | $128,208 |
| Xeljanz XrTofacitinib Citrate | 19 | $110,012 |
| Enbrel MiniEtanercept | 13 | $94,110 |
| SimponiGolimumab | 13 | $91,730 |
| Orencia ClickjectAbatacept | 11 | $87,269 |
| BenlystaBelimumab | 15 | $72,837 |
| OtezlaApremilast | 12 | $54,735 |
| Hydroxychloroquine Sulfate | 475 | $13,454 |
| MethotrexateMethotrexate Sodium | 347 | $7,760 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $24,022 | $474,02859 claims |
| UCB, Inc.Cimzia (2 Pack) | $860 | $181,63819 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $960 | $128,20822 claims |
| Johnson & JohnsonSimponi | $781 | $91,73013 claims |
| GSKBenlysta | $54,712 | $72,83715 claims |
| AmgenOtezla | $2,404 | $54,73512 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $45 | $1,84769 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 210 rheumatology providers in North Carolina.
Other rheumatology in Charlotte
- Gordon LamCharlotte$2.7M
- Andrew LasterCharlotte$421K
- Jill ZouzoulasCharlotte$377K
- Charles WithersCharlotte$136K
- Firas KassabCharlotte$80K
- Alireza NamiCharlotte$45K
- Amit PatelCharlotte$18K
- John BrendeseCharlotte$18K
- Diane GeorgeCharlotte$16K
- Eric OrlowskyCharlotte$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.